Vol 72, No 3 (2021)
Editorial
Published online: 2021-06-30

open access

Page views 728
Article views/downloads 643
Get Citation

Connect on Social Media

Connect on Social Media

The treatment of heterozygous familial hypercholesterolemia — a local perspective

Łukasz Bułdak1
Pubmed: 34292576
Endokrynol Pol 2021;72(3):189-190.

Abstract

none

Article available in PDF format

View PDF Download PDF file

References

  1. Dyrbuś K, Gąsior M, Desperak P, et al. The prevalence and management of familial hypercholesterolemia in patients with acute coronary syndrome in the Polish tertiary centre: Results from the TERCET registry with 19,781 individuals. Atherosclerosis. 2019; 288: 33–41.
  2. Haase A, Goldberg AC. Identification of people with heterozygous familial hypercholesterolemia. Curr Opin Lipidol. 2012; 23(4): 282–289.
  3. Krajowe Centrum Hipercholesterolemii Rodzinnej. http://hipercholesterolemia.com.pl/Kontakt,67 (11.05.2021).
  4. Bułdak Ł, Marek B, Kajdaniuk D, et al. Endocrine diseases as causes of secondary hyperlipidemia. Endokrynol Pol. 2019; 70(6): 511–519.
  5. Hennig M, Brandt-Varma A, Wołoszyn-Durkiewicz A, et al. Monitoring the Effects of Hypolipidemic Treatment in Children with Familial Hypercholesterolemia in Poland. Life (Basel). 2020; 10(11).
  6. Averna M, Banach M, Bruckert E, et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis. 2021 [Epub ahead of print].
  7. Zygmunt A, Dąbrowski J, Lewiński A. Specialist thyroid package 1 (PS1) in outpatient endocrine care. Endokrynol Pol. 2020; 71(6): 485–496.
  8. Leczenie inhibitorami PCSK-9 pacjentów z zaburzeniami lipidowymi (ICD-10 E78.01, I21, I22, I25). https://www.gov.pl/attachment/9ad24526-c366-4b32-b4b0-8eb9a62c9d00 (11.05.2021).
  9. Brandts J, Dharmayat K, Vallejo-Vaz A, et al. A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. Atherosclerosis. 2021; 325: 46–56.
  10. Cordero A, Rodríguez-Mañero M, Fácila L, et al. Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials. J Diabetes Metab Disord. 2020; 19(2): 759–765.
  11. Okopień B, Bułdak Ł, Bołdys A. Current and future trends in the lipid lowering therapy. Pharmacol Rep. 2016; 68(4): 737–747.
  12. Banach M, Duell PB, Gotto AM, et al. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. JAMA Cardiol. 2020; 5(10): 1124–1135.
  13. Surma S, Romańczyk M, Filipiak KJ. Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia. Cardiol J. 2021 [Epub ahead of print].